1. U.S. Food and Drug Administration. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss [press release]. 2017 Dec 18. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss.
2. Spark Therapeutics. FDA approves spark therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a one-time gene therapy for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy [press release]. 2017 Dec 19. Available from: https://sparktx.com/press_releases/fda-approves-spark-therapeutics-luxturna-voretigene-neparvovec-rzyl-a-one-time-gene-therapy-for-patients-with-confirmed-biallelic-rpe65-mutation-associated-retinal-dystrophy/.
3. Ciulla T. Gene therapy implications for retina specialists: evolving endpoints, novel orphan disease treatment paradigms, and the dawn of precision medicine. Retinal physician [Internet]. 2019. Available from: https://www.retinalphysician.com/issues/2019/march-2019/gene-therapy-implications-for-retina-specialists.
4. Hirschler B. $1 million price tag in spotlight as gene therapy becomes reality. Reuters [Internet]. 2017 Dec 16. Available from: https://www.reuters.com/article/us-health-gene-therapy/1-million-price-tag-in-spotlight-as-gene-therapy-becomes-reality-idUSKBN1DG2HL.
5. Berkrot B. Spark’s price for Luxturna blindness gene therapy too high: ICER. Reuters [Internet]. 2018 Jan 12. Available from: https://www.reuters.com/article/us-spark-icer/sparks-price-for-luxturna-blindness-gene-therapy-too-high-icer-idUSKBN1F1298.